Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte(TM) for the Treatment of Cutaneous T-Cell Lymphoma

Following the first Phase 3 study of HyBryte(TM) for the treatment of CTCL, the FDA and the EMA indicated that they would require a second successful Phase 3 trial to support mark ...
ascopubs.org

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary ...

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Subcutaneous amivantamab-lazertinib demonstrated noninferior ...
IEEE

Development of a Half-Bridge Cell-Derived All-Inclusive Conducted Emission Noise Model for SiC-Based Single Phase Boost PFC Converter

Abstract: This work presents a novel all-inclusive power electronic converter noise model comprised of both differential-mode (DM) and common-mode (CM) parasitic circuit components. Furthermore, a ...
Asheville Citizen-Times

Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma

CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...
The EMBO Journal

Cell cycle criticality as a mechanism for robust cell population control

This month's cover highlights the article Epigenomic landscape of single vascular cells reflects developmental origin and disease risk loci by Chad Weldy, Thomas Quertermous and colleagues. This image ...